Literature DB >> 2901022

Feeding elicited by dynorphin (1-13) microinjections into the ventral tegmental area in rats.

M E Hamilton1, M A Bozarth.   

Abstract

Both the endogenous opioid peptide, dynorphin (1-13) (DYN), and morphine elicited dose-dependent feeding when microinjected into the ventral tegmental area of food-satiated rats. DYN was 50,000 times more potent than morphine in producing feeding. Whereas the ED50 for morphine was in the nanomole range, the ED50 for DYN was in the femtomole range. Administration of a narcotic antagonist attenuated DYN-elicited feeding. These data suggest a possible role for DYN in the VTA in opioid modulation of feeding behavior.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901022     DOI: 10.1016/0024-3205(88)90271-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors.

Authors:  David H Root; Roberto I Melendez; Laszlo Zaborszky; T Celeste Napier
Journal:  Prog Neurobiol       Date:  2015-04-06       Impact factor: 11.685

2.  Challenges and new opportunities for detecting endogenous opioid peptides in reward.

Authors:  Sineadh M Conway; Marwa O Mikati; Ream Al-Hasani
Journal:  Addict Neurosci       Date:  2022-04-03

3.  Striatal regulation of morphine-induced hyperphagia: an anatomical mapping study.

Authors:  V P Bakshi; A E Kelley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 4.  Dopamine, morphine, and nitric oxide: an evolutionary signaling triad.

Authors:  George B Stefano; Richard M Kream
Journal:  CNS Neurosci Ther       Date:  2009-11-13       Impact factor: 5.243

Review 5.  kappa-Opioid receptor signaling and brain reward function.

Authors:  Adrie W Bruijnzeel
Journal:  Brain Res Rev       Date:  2009-10-02

Review 6.  Does the kappa opioid receptor system contribute to pain aversion?

Authors:  Catherine M Cahill; Anna M W Taylor; Christopher Cook; Edmund Ong; Jose A Morón; Christopher J Evans
Journal:  Front Pharmacol       Date:  2014-11-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.